Overall, these findings in the Vk*MYC mouse support a model in which aggressive and genomically unstable MM are less sensitive to anti-BCMA TCE therapy due to downregulation of their plasma cell identity, including BCMA expression, thereby evading treatment pressure. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.